AgeX Therapeutics Files 8-K: Stockholder Meeting, Bylaw Changes
Ticker: SER · Form: 8-K · Filed: Mar 14, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Agex Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Mar 14, 2024 |
| Risk Level | medium |
| Pages | 10 |
| Reading Time | 12 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, stockholder-meeting, bylaws
TL;DR
AgeX filed an 8-K covering stockholder meeting results and potential bylaw/charter changes. Keep an eye on those rights modifications.
AI Summary
On March 14, 2024, AgeX Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockholders, including the election of directors and the ratification of its independent registered public accounting firm. Additionally, the filing indicates potential material modifications to the rights of security holders and amendments to its articles of incorporation or bylaws, though specific details are not provided in this excerpt.
Why It Matters
This filing provides updates on corporate governance and potential changes to shareholder rights, which are crucial for investors to understand the company's structure and their standing.
Risk Assessment
Risk Level: medium — The filing mentions potential material modifications to rights of security holders and amendments to governing documents, which could significantly impact investors.
Key Players & Entities
- AgeX Therapeutics, Inc. (company) — Registrant
- March 14, 2024 (date) — Date of Report
FAQ
What were the specific outcomes of the AgeX Therapeutics annual meeting of stockholders?
The filing indicates that the annual meeting of stockholders was held, and it included the election of directors and the ratification of the company's independent registered public accounting firm. Specific vote counts or resolutions are not detailed in this excerpt.
What are the 'Material Modifications to Rights of Security Holders' mentioned in the filing?
The filing lists 'Material Modifications to Rights of Security Holders' as an item of disclosure, but the specific nature of these modifications is not detailed in the provided text.
What amendments were made to AgeX Therapeutics' Articles of Incorporation or Bylaws?
The filing indicates that there were 'Amendments to Articles of Incorporation or Bylaws' reported, but the specific changes are not elaborated upon in this excerpt.
What is the significance of the 'Submission of Matters to a Vote of Security Holders' item?
This item signifies that matters were presented to and voted upon by the company's security holders during the reported period, likely related to the annual meeting.
Where is AgeX Therapeutics, Inc. incorporated and what is its principal executive office address?
AgeX Therapeutics, Inc. is incorporated in Delaware and its principal executive office is located at 1101 Marina Village Parkway, Suite 201, Alameda, California 94501.
Filing Stats: 3,118 words · 12 min read · ~10 pages · Grade level 18.3 · Accepted 2024-03-14 16:12:57
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share AGE NYSE American Check
Filing Documents
- form8-k.htm (8-K) — 106KB
- ex3-1.htm (EX-3.1) — 14KB
- 0001493152-24-009959.txt ( ) — 305KB
- age-20240314.xsd (EX-101.SCH) — 3KB
- age-20240314_lab.xml (EX-101.LAB) — 33KB
- age-20240314_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGEX THERAPEUTICS, INC. Date: March 14, 2024 By: /s/ Andrea E. Park Chief Financial Officer